The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
The S&P 500 (^GSPC) is full of established businesses, but only some continue to outperform the market.
A few standout companies are thriving thanks to strong fundamentals and sustained competitive advantages.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Incyte’s fourth quarter was met with a negative market reaction, despite the company delivering revenue growth above Wall Street expectations. Management attributed this performance to strong commercial execution across its core products, notably Jakafi and Opsalura, as well as significant progress in the late-stage development pipeline. CEO William Meury highlighted that growth was broad-based, with almost every major product contributing, and commercial milestones were achieved across both established and newly launched therapies. However, higher research and development (R&D) spending and increased operating expenses weighed on margins, partially offsetting the top-line gains.
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the Delaware-based biopharmaceutical giant is currently undergoing a radical transformation. Today, the stock is under heavy scrutiny following yesterday’s fiscal year 2025 earnings report. While [...]
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share was 6.1% below analysts’ consensus estimates.
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
fell 8.8% in the morning session after the company reported mixed fourth-quarter 2025 results, where a significant revenue beat was overshadowed by an earnings miss. The company's adjusted earnings per share (EPS) came in at $1.80, falling short of Wall Street's consensus estimate of $1.92. This earnings shortfall appeared to be the primary concern for investors, despite revenue showing strong performance. Sales for the quarter grew 27.8% year-over-year to $1.51 billion, comfortably surpassing analysts' expectations. Adding to the pressure, the company's operating margin contracted to 22.3% from 25.6% in the same period last year, indicating that expenses grew faster than revenue.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share was 6.1% below analysts’ consensus estimates.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
will be announcing earnings results this Tuesday before market open. Here’s what to look for.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
